First Patient Enrolled in New World-First Study into Prostate Cancer

Reno, Nevada ( -- The first of a planned 100 patients have been enrolled in a new cancer trial for the treatment of people with metastatic castration–resistant prostate cancer.

The EVOLUTION (ANZUP 2001) trial, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), in partnership with the Prostate Cancer Foundation of Australia (PCFA), screened its first patient at Peter MacCallum Cancer Centre in Melbourne.

Prostate cancer remains the most common cancer and the second commonest cause of cancer related death in Australian men.

The purpose of this study is to see if combining ipilimumab and nivolumab (drugs that activate the body’s own immune response to kill cancer cells), with 177Lu-PSMA (a type of treatment called radionuclide therapy that can be used to treat prostate cancer by bringing radioactive atoms into the cancer cells), can further improve the anti-cancer effects of 177Lu-PSMA.

This new treatment combination may lead to shrinkage or stabilisation of previously progressing tumours and therefore hopefully stop or reverse the growth of the cancer.

The new randomised phase 2 study will also determine the activity and safety of ipilimumab and nivolumab in combination with 177Lu-PSMA in patients with metastatic castration resistant prostate cancer (mCRPC).

“We’re excited to be opening the first ever study to test the effectiveness of combining 177Lu-PSMA with cancer immunotherapy. This study has the potential to lead to better and more durable responses for people with prostate cancer,” said Associate Professor Shahneen Sandhu, Principal Investigator.

“EVOLUTION continues ANZUP’s mission of improving outcomes for people affected by prostate and other genitourinary cancers. This great collaboration brings together ANZUP, PCFA, our community of clinicians and researchers, and people directly affected by prostate cancer, to learn from what has gone before and to take new steps forward together. Clinical trials like EVOLUTION are the only way we make true progress in medical care,” said Professor Ian Davis, ANZUP Chair.
“We are on the verge of a complete transformation in prostate cancer treatment, giving people with the most aggressive and deadly forms of this disease a greater hope of survival. PCFA’s partnership with ANZUP has led much of this work over recent years, establishing Australian researchers as global leaders in this field and enabling more Australian people to live longer and better with prostate cancer. PCFA is proud to be part of this innovative new trial,” said PCFA CEO, Anne Savage.

The first patient enrolled marks the start of the journey to recruit and follow up 100 eligible patients across 9 cancer centres across Australia.

Source: "News – ANZUP". 2022. ANZUP.
email news signup